about
Statins for osteoporosis in postmenopausal womenDoes design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studiesThe "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst.Does simvastatin stimulate bone formation in vivo?Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598]Statins as modulators of bone formation.The role of statins as potential targets for bone formationHigh Cholesterol Deteriorates Bone Health: New Insights into Molecular MechanismsNuclear receptors in bone physiology and diseasesOngoing clinical trials of the pleiotropic effects of statinsHydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management.Hyperlipidemia impairs osteoanabolic effects of PTH.Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss.Recent advances: rheumatology.Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT projectEffect of acetylcholinesterase inhibitors on post-surgical complications and mortality following a hip fracture: a cohort study.Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch databaseStatins and bones.Osseointegration in arthroplasty: can simvastatin promote bone response to implants?Semisynthesis of novel monacolin J derivatives: hypocholesterolemic and neuroprotective activities.Is lipid profile associated with bone mineral density and bone formation in subjects with spinal cord injury?Pharmacology and clinical experience with simvastatin.Nutraceutical fatty acids as biochemical and molecular modulators of skeletal biology.Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.Statins and osteoporosis: new role for old drugs.Potential use of HMG-CoA reductase inhibitors for osteoporosis.Prescribing for seniors: it's a balancing act.Statins: mechanism of action and effects.Novel therapies for osteoporosis.Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.Predictors of mortality subsequent to a fracture in diabetes mellitus patients.Epidemiology of lower limb fractures in general practice in the United Kingdom.Association between dietary fat intake and bone mineral density in Korean adults: data from Korea National Health and Nutrition Examination Survey IV (2008 ∼ 2009).Lipid-lowering agents and the risk of hip fracture in a Medicaid population.Statin use and the risk of colorectal cancer: a population-based case-control studyIsoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.Association between atherosclerosis and osteoporosis, the role of vitamin DLinks between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se?Statin use and risk of fracture: a meta-analysis.Protective Effects of Simvastatin Against Alendronate-Induced Gastric Mucosal Injury in Rats.
P2860
Q24243698-1B640133-957E-43A3-821C-C32CF4FD3230Q24288975-36C398AA-E84E-49BB-8BB6-35920C2F2662Q24796000-7AF95347-039D-4C51-BFA9-6225FE9FBA37Q24801282-945EBA0A-B908-45A8-A6E9-0BBC6E35B494Q24803192-8C52787E-3308-4ED6-A89E-0C1455B4ECEAQ24806116-3ADB813E-66CF-4D21-9E30-F1E09569427FQ24806198-012B041C-9729-4680-9DB4-269D419EE7BFQ26777956-6378AF10-F389-418E-822A-7792C21150ABQ26853017-AD7C4AEC-A50B-4B38-AD4A-169898409B24Q28219321-2197DB38-45E6-40B2-AD00-601FA257B1C3Q30308718-6B52C60A-F1F0-4215-B262-85518BDCC511Q33337922-32EA4B9F-1592-494C-9535-6FB386D7A9F2Q33585814-748F60E8-B45C-4DC8-AA8E-E6B79C422DF5Q33802220-871BFBA8-24D1-4872-AE55-1562BEA03549Q33851671-F47DE183-7122-4B4A-9E43-46E832748EB7Q33856939-137EBA20-FCD0-4592-8D37-4C9014304A18Q33867311-44961EA8-C8FE-44E9-A3A6-08BE1AEB116EQ33955458-EA8EA7A7-D1D1-4FF5-964D-50F4DC76AAECQ33989769-A520243E-168B-4691-A49B-86FBEED04927Q34127245-F6EB7832-599B-4667-BACF-074EE05C2DF2Q34152054-9533D954-9D74-4F8A-9FAB-2E93FBB0255AQ34240784-6DDA3557-A96E-494A-87F4-1A43376C0785Q34402915-126850AB-8EAF-423A-9495-D429DF941521Q34411415-2CC47D69-3F09-44D0-A7F5-041563CF661FQ34563901-39E4CEFE-7066-425E-AA70-B6A2350DE302Q34579635-B4E71C2D-661D-4967-8DDB-C301F2BAC0F1Q34586084-D389DAD7-986E-4E4E-8E6D-4D8FECFE7CAAQ34687736-73173E28-84AC-4F9E-8B56-554A647FEA8BQ35094675-1413FB69-DA02-446F-8AFE-F1F8CF3EF50DQ35229889-B7197A0B-434F-485C-9170-D212AF5CD9E9Q35239015-7D15705D-651C-4E63-A824-32C72A95C3EBQ35383647-93938576-A3B0-4ECF-ACB2-EBD605FFD37FQ35505600-B8CE70F7-017C-4868-B402-2F74F7B9A355Q35557793-6934C04A-C7EA-47E8-A317-23275AADF170Q35627285-6DE84CA0-6C07-4B76-BE50-FC4E4B9CE4A3Q35634151-395F524A-C6A7-4166-A287-53F21C8AB855Q35674067-AD5BC045-6696-4734-8A95-13BA2AFD169BQ35676929-4B4A560F-5A40-4A87-95DD-0AD10FED5814Q35722086-62CF550F-241A-458D-9D47-C6379C5B1B2FQ35786941-D3586178-9D04-4F37-BCE6-C441277CE0DF
P2860
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
HMG-CoA reductase inhibitors and the risk of fractures.
@en
type
label
HMG-CoA reductase inhibitors and the risk of fractures.
@en
prefLabel
HMG-CoA reductase inhibitors and the risk of fractures.
@en
P2093
P356
P1476
HMG-CoA reductase inhibitors and the risk of fractures.
@en
P2093
B Schlegel
M E Kraenzlin
R G Schlienger
P304
P356
10.1001/JAMA.283.24.3205
P407
P50
P577
2000-06-01T00:00:00Z